|
|
Blood, 15 June 2008, Vol. 111, No. 12, pp. 5477-5485.
Prepublished online as a Blood First Edition Paper on April 3, 2008; DOI 10.1182/blood-2008-01-132837.
 Previous Article | Table of Contents | Next Article 
CLINICAL TRIALS AND OBSERVATIONS
Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study
Michael J. Borowitz1,
Meenakshi Devidas2,
Stephen P. Hunger3,
W. Paul Bowman4,
Andrew J. Carroll5,
William L. Carroll6,
Stephen Linda2,
Paul L. Martin7,
D. Jeanette Pullen8,
David Viswanatha9,
Cheryl L. Willman10,
Naomi Winick11,
Bruce M. Camitta12, for the Children's Oncology Group13
1 Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD;
2 Children's Oncology Group and the College of Medicine, University of Florida, Gainesville;
3 University of Colorado Denver and The Children's Hospital, Aurora;
4 Cook Children's Hospital, Fort Worth, TX;
5 University of Alabama at Birmingham;
6 New York University School of Medicine, New York, NY;
7 Duke University School of Medicine, Durham, NC;
8 University of Mississippi School of Medicine, Jackson;
9 Mayo Clinic, Rochester, MN;
10 University of New Mexico School of Medicine, Albuquerque;
11 University of Texas Southwestern School of Medicine, Dallas;
12 Midwest Children's Cancer Center, Medical College of Wisconsin, Milwaukee; and
13 Children's Oncology Group, Arcadia, CA
Minimal residual disease (MRD) is an important predictor of relapse in acute lymphoblastic leukemia (ALL), but its relationship to other prognostic variables has not been fully assessed. The Children's Oncology Group studied the prognostic impact of MRD measured by flow cytometry in the peripheral blood at day 8, and in end-induction (day 29) and end-consolidation marrows in 2143 children with precursor B-cell ALL (B-ALL). The presence of MRD in day-8 blood and day-29 marrow MRD was associated with shorter event-free survival (EFS) in all risk groups; even patients with 0.01% to 0.1% day-29 MRD had poor outcome compared with patients negative for MRD patients (59% ± 5% vs 88% ± 1% 5-year EFS). Presence of good prognostic markers TEL-AML1 or trisomies of chromosomes 4 and 10 still provided additional prognostic information, but not in National Cancer Insitute high-risk (NCI HR) patients who were MRD+. The few patients with detectable MRD at end of consolidation fared especially poorly, with only a 43% plus or minus 7% 5-year EFS. Day-29 marrow MRD was the most important prognostic variable in multi-variate analysis. The 12% of patients with all favorable risk factors, including NCI risk group, genetics, and absence of days 8 and 29 MRD, had a 97% plus or minus 1% 5-year EFS with nonintensive therapy. These studies are registered at www.clinicaltrials.gov as NCT00005585
[ClinicalTrials.gov]
, NCT00005596
[ClinicalTrials.gov]
, and NCT00005603
[ClinicalTrials.gov]
.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
A. V. Kurtova, K. Balakrishnan, R. Chen, W. Ding, S. Schnabl, M. P. Quiroga, M. Sivina, W. G. Wierda, Z. Estrov, M. J. Keating, et al.
Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance
Blood,
November 12, 2009;
114(20):
4441 - 4450.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Muzzafar, L. J. Medeiros, S. A. Wang, A. Brahmandam, D. A. Thomas, and J. L. Jorgensen
Aberrant Underexpression of CD81 in Precursor B-Cell Acute Lymphoblastic Leukemia: Utility in Detection of Minimal Residual Disease by Flow Cytometry
Am J Clin Pathol,
November 1, 2009;
132(5):
692 - 698.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Basso, M. Veltroni, M. G. Valsecchi, M. N. Dworzak, R. Ratei, D. Silvestri, A. Benetello, B. Buldini, O. Maglia, G. Masera, et al.
Risk of Relapse of Childhood Acute Lymphoblastic Leukemia Is Predicted By Flow Cytometric Measurement of Residual Disease on Day 15 Bone Marrow
J. Clin. Oncol.,
November 1, 2009;
27(31):
5168 - 5174.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. R. Schultz, W. P. Bowman, A. Aledo, W. B. Slayton, H. Sather, M. Devidas, C. Wang, S. M. Davies, P. S. Gaynon, M. Trigg, et al.
Improved Early Event-Free Survival With Imatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Children's Oncology Group Study
J. Clin. Oncol.,
November 1, 2009;
27(31):
5175 - 5181.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C.-H. Pui
Toward a Total Cure for Acute Lymphoblastic Leukemia
J. Clin. Oncol.,
November 1, 2009;
27(31):
5121 - 5123.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Grimwade, J. V. Jovanovic, R. K. Hills, E. A. Nugent, Y. Patel, R. Flora, D. Diverio, K. Jones, H. Aslett, E. Batson, et al.
Prospective Minimal Residual Disease Monitoring to Predict Relapse of Acute Promyelocytic Leukemia and to Direct Pre-Emptive Arsenic Trioxide Therapy
J. Clin. Oncol.,
August 1, 2009;
27(22):
3650 - 3658.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. C. Bene and J. S. Kaeda
How and why minimal residual disease studies are necessary in leukemia: a review from WP10 and WP12 of the European LeukaemiaNet
Haematologica,
August 1, 2009;
94(8):
1135 - 1150.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. G. Mullighan, J. Zhang, R. C. Harvey, J. R. Collins-Underwood, B. A. Schulman, L. A. Phillips, S. K. Tasian, M. L. Loh, X. Su, W. Liu, et al.
JAK mutations in high-risk childhood acute lymphoblastic leukemia
PNAS,
June 9, 2009;
106(23):
9414 - 9418.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. A. Scrideli, J. G. Assumpcao, M. A. Ganazza, M. Araujo, S. R. Toledo, M. L. M. Lee, E. Delbuono, A. S. Petrilli, R. P. Queiroz, A. Biondi, et al.
A simplified minimal residual disease polymerase chain reaction method at early treatment points can stratify children with acute lymphoblastic leukemia into good and poor outcome groups
Haematologica,
June 1, 2009;
94(6):
781 - 789.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Bassan, O. Spinelli, E. Oldani, T. Intermesoli, M. Tosi, B. Peruta, G. Rossi, E. Borlenghi, E. M. Pogliani, E. Terruzzi, et al.
Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)
Blood,
April 30, 2009;
113(18):
4153 - 4162.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. G. Mullighan, X. Su, J. Zhang, I. Radtke, L. A.A. Phillips, C. B. Miller, J. Ma, W. Liu, C. Cheng, B. A. Schulman, et al.
Deletion of IKZF1 and Prognosis in Acute Lymphoblastic Leukemia
N. Engl. J. Med.,
January 29, 2009;
360(5):
470 - 480.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. J. Yang, D. Bhojwani, W. Yang, X. Cai, G. Stocco, K. Crews, J. Wang, D. Morrison, M. Devidas, S. P. Hunger, et al.
Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia
Blood,
November 15, 2008;
112(10):
4178 - 4183.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. N. Dworzak, A. Schumich, D. Printz, U. Potschger, Z. Husak, A. Attarbaschi, G. Basso, G. Gaipa, R. Ratei, G. Mann, et al.
CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy
Blood,
November 15, 2008;
112(10):
3982 - 3988.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. A. Raetz, M. J. Borowitz, M. Devidas, S. B. Linda, S. P. Hunger, N. J. Winick, B. M. Camitta, P. S. Gaynon, and W. L. Carroll
Reinduction Platform for Children With First Marrow Relapse of Acute Lymphoblastic Leukemia: A Children's Oncology Group Study
J. Clin. Oncol.,
August 20, 2008;
26(24):
3971 - 3978.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Tucci and M. Arico
Treatment of pediatric acute lymphoblastic leukemia
Haematologica,
August 1, 2008;
93(8):
1124 - 1128.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Campana
Molecular Determinants of Treatment Response in Acute Lymphoblastic Leukemia
Hematology,
January 1, 2008;
2008(1):
366 - 373.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
